BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Tävling: Delta i Börskollens jultävling – vinn fina priser från Sonos och Börsdata

Pressmeddelande

BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease

Cision Publicerad: 26 Aug 08:46
Abliva

Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva’s development moving forward.

Watch the interview with Abliva’s CEO Ellen Donnelly at biostock.se:

Abliva's CEO: We are the leading programme in mitochondrial disease - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Abliva

Läses av andra just nu

Om aktien Abliva

Senaste nytt